PDS Biotechnology (NASDAQ:PDSB) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

PDS Biotechnology (NASDAQ:PDSB) issued its earnings results on Monday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06, FiscalAI reports.

PDS Biotechnology Price Performance

PDSB stock opened at $0.54 on Monday. The company has a 50 day moving average of $0.72 and a two-hundred day moving average of $0.86. The company has a market cap of $28.36 million, a price-to-earnings ratio of -0.66 and a beta of 1.20. PDS Biotechnology has a 12-month low of $0.52 and a 12-month high of $1.92. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 1.26.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

A number of hedge funds have recently modified their holdings of PDSB. Virtu Financial LLC acquired a new stake in PDS Biotechnology during the fourth quarter valued at $25,000. Armistice Capital LLC acquired a new position in PDS Biotechnology in the 4th quarter worth about $2,182,000. Commonwealth Equity Services LLC increased its position in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after purchasing an additional 106,300 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of PDS Biotechnology by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after purchasing an additional 38,399 shares in the last quarter. Finally, Susquehanna International Group LLP lifted its holdings in shares of PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after buying an additional 80,937 shares during the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.